Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KaloBios Rises From Bankruptcy Ashes With PRV Still Firmly In Its Sights

Executive Summary

KaloBios Pharmaceuticals Inc.'s CEO Dr Cameron Durrant has ticked off two major tasks from his to-do list in his bid to turn the company around after it was caught in the firestorm of Martin Shkreli's fall from grace. He talks to Scrip about the company's strategy, his vision of a responsible pricing model, and the possibility that KaloBios' actions might help rehabilitate pharma's image.

Advertisement

Related Content

KaloBios Can Get Priority Review Voucher With 505(b)(2) Chagas Application
More Than 'That Old Shkreli Co.,' KaloBios Ready To Innovate, Change Biotech
Shkreli's Empire Collapses: KaloBios Seeks Bankruptcy Protection
Gilead pays unprecedented $125m for Knight priority voucher
FDA OK's Impavido in leishmaniasis; Knight wins priority voucher

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel